Jennifer Champoux

CIK: 0002025233

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (46.2%)

Position reduction

Option Exercises (M)5 (38.5%)

Derivative conversions

Awards (A)2 (15.4%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

GLUE

Monte Rosa Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (13 total)

GLUE
Monte Rosa Therapeutics, Inc.
Jul 15, 2026
Sale(S)
Direct
4.4K shares at avg. $23.38$102K
GLUE
Monte Rosa Therapeutics, Inc.
Jul 15, 2026
Exercise(M)
Direct
4.4K shares at avg. $3.98$17K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 23, 2026
Exercise(M)
Direct
2.2K shares at avg. $3.98$9K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 23, 2026
Sale(S)
Direct
2.2K shares at avg. $20.00$44K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 17, 2026
Exercise(M)
Direct
2.2K shares at avg. $3.98$9K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 17, 2026
Sale(S)
Direct
2.2K shares at avg. $19.00$41K
GLUE
Monte Rosa Therapeutics, Inc.
May 27, 2026
Exercise(M)
Direct
2.2K shares at avg. $3.98$9K
GLUE
Monte Rosa Therapeutics, Inc.
May 27, 2026
Sale(S)
Direct
2.2K shares at avg. $20.00$44K
GLUE
Monte Rosa Therapeutics, Inc.
May 22, 2026
Exercise(M)
Direct
2.2K shares at avg. $3.98$9K
GLUE
Monte Rosa Therapeutics, Inc.
May 22, 2026
Sale(S)
Direct
2.2K shares at avg. $19.00$41K
GLUE
Monte Rosa Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
2.6K shares at avg. $15.17$40K
GLUE
Monte Rosa Therapeutics, Inc.
Jan 2, 2026
Award(A)
Direct
35K shares-
GLUE
Monte Rosa Therapeutics, Inc.
Jan 2, 2025
Award(A)
Direct
30K shares-

		Type	Shares	Price		Ownership
Jul 15, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	4,351	$23.38	$101,730	Direct
Jul 15, 2026	GLUE Monte Rosa Therapeutics, Inc.	Exercise(M)	4,351	$3.98	$17,317	Direct
Jun 23, 2026	GLUE Monte Rosa Therapeutics, Inc.	Exercise(M)	2,175	$3.98	$8,657	Direct
Jun 23, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	2,175	$20.00	$43,500	Direct
Jun 17, 2026	GLUE Monte Rosa Therapeutics, Inc.	Exercise(M)	2,176	$3.98	$8,660	Direct
Jun 17, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	2,176	$19.00	$41,344	Direct
May 27, 2026	GLUE Monte Rosa Therapeutics, Inc.	Exercise(M)	2,175	$3.98	$8,657	Direct
May 27, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	2,175	$20.00	$43,500	Direct
May 22, 2026	GLUE Monte Rosa Therapeutics, Inc.	Exercise(M)	2,176	$3.98	$8,660	Direct
May 22, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	2,176	$19.00	$41,344	Direct
Jan 5, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	2,629	$15.17	$39,882	Direct
Jan 2, 2026	GLUE Monte Rosa Therapeutics, Inc.	Award(A)	35,000	-	$0	Direct
Jan 2, 2025	GLUE Monte Rosa Therapeutics, Inc.	Award(A)	30,000	-	$0	Direct

1-13 of 13 transactions

About Champoux Jennifer

Champoux Jennifer (SEC CIK 0002025233) files insider reports with the SEC as Chief Operating Officer of Monte Rosa Therapeutics, Inc. (GLUE).

Signal8 holds 7 ownership filings by Champoux Jennifer, all Form 4s, filed between Jan 6, 2025 and Jul 16, 2026. Those filings report 13 transactions, from Jan 2, 2025 to Jul 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Champoux Jennifer's filings is in BOSTON, MA.

Recent filings by Champoux Jennifer

Jul 15, 2026: Open-market sale of GLUE shares (Form 4, code S).
Jul 15, 2026: Option exercise of GLUE shares (Form 4, code M).
Jun 23, 2026: Option exercise of GLUE shares (Form 4, code M).
Jun 23, 2026: Open-market sale of GLUE shares (Form 4, code S).
Jun 17, 2026: Option exercise of GLUE shares (Form 4, code M).

Other insiders filing for Monte Rosa Therapeutics, Inc. (GLUE)

Bowen Matthew, Principal Accounting Officer
Warmuth Markus, President & CEO
Townson Sharon, Chief Scientific Officer
Behbahani Ali, Director
Janku Filip, Chief Medical Officer
SCHIFF ANDREW N, Director

How to read Form 4 transaction codes